Impact of Complete Revascularization on Development of Heart Failure in Patients With Acute Coronary Syndrome and Multivessel Disease: A Subanalysis of the CORALYS Registry
The effects of CR on the occurrence of HF in patients with acute coronary syndrome and multivessel coronary artery disease who undergo percutaneous coronary intervention have yet to be fully understood. The subanalysis of the CORALYS (Incidence and Predictors of Heart Failure After Acute Coronary Syndrome) registry aimed to evaluate the impact of complete revascularization (CR) on adverse outcomes at follow-up for patients with acute coronary syndrome (ACS) and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI). Out of the 14,699 patients in the registry, 5,054 presented with multivessel disease. This study found that in patients with both ST-segment elevation myocardial infarction and non-ST-elevation acute coronary syndrome, complete revascularization reduced the risk of first hospitalization for heart failure and cardiovascular death, as well as first heart failure hospitalization, and cardiovascular and overall death. These findings suggest that complete revascularization may be beneficial for reducing adverse outcomes in patients with ACS and multivessel disease who undergo PCI.
Forecasting the Risk of Heart Failure Hospitalization After Acute Coronary Syndromes: the CORALYS HF Score
The CORALYS HF score, which takes into account variables easily accessible at discharge, was used to identify patients at a higher risk of hospitalization for heart failure (HF) in a population of patients with acute coronary syndrome (ACS) treated with percutaneous coronary revascularization. The study, conducted from 2015 to 2020, included 14,699 patients, of which 593 (4.0%) were admitted for HF within 1 year after the index ACS presentation. The results of this study could help healthcare providers identify and monitor high-risk patients to prevent or manage HF-related hospitalizations
Diffuse coronary artery disease management with drug-coated balloons
While drug-coated balloons (DCB) may seem like a promising alternative to drug-eluting stents, there is still limited evidence and research in the use of DCB for larger vessel disease. In fact, the effectiveness of DCB in treating complex lesions, such as bifurcations, chronic total occlusions, and diffuse, long lesions, remains uncertain. Additionally, while DCB may be a viable option for diffuse coronary disease, it is important to consider all treatment options and individual patient factors before deciding on a DCB strategy. Therefore, this paper aimed review all the current evidences of DCB in diffuse CAD managements.
The evolution and revolution of drug coated balloons in coronary angioplasty: An up‐to‐date review of literature data
The use of drug-coated balloons (DCB) has been recommended by the European Society of Cardiology (ESC) for in-stent restenosis, but there is no indication for their usage in de novo lesions. Despite this, DCB offer a promising alternative to stents as they do not require a permanent implant of metal or polymer. They have already been in use in Europe and Asia, and have been approved for clinical trials in the United States specifically for restenotic lesions. There is also emerging data showing that DCB may be noninferior, and in some cases even superior, to current generation drug-eluting stents (DES) in small vessels. This article provided a comprehensive review of the literature on this expanding technology, focusing on the evidence for both restenotic and de novo lesions.
Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease
Sodium-glucose cotransporter 2 inhibitors (SGLTi) were initially developed as a treatment for type 2 diabetes, but their use has now expanded to include patients with cardiovascular disease (CVD). In fact, these drugs have shown positive results in reducing symptoms and improving overall health in patients with CVD. This has led to a shift in focus from treating just diabetes to also addressing other conditions such as heart failure. As a result, SGLT2 inhibitors have become a valuable tool in managing not only diabetes, but also heart disease and chronic kidney disease. This article will delve into the mechanisms and benefits of SGLT2 inhibitors and their role in improving the health of patients with multiple conditions.